Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies the side effects and best dose of magrolimab and venetoclax
when given together with azacitidine and to see how well they work in treating patients with
acute myeloid leukemia. Magrolimab is a monoclonal antibody that may interfere with the
ability of cancer cells to grow and spread. Chemotherapy drugs, such as azacitidine, work in
different ways to stop the growth of cancer cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Venetoclax may stop the growth of
cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving magrolimab,
azacitidine, and venetoclax may help to control the disease.